CAPTOPRIL tablet

국가: 미국

언어: 영어

출처: NLM (National Library of Medicine)

유효 성분:

CAPTOPRIL (UNII: 9G64RSX1XD) (CAPTOPRIL - UNII:9G64RSX1XD)

제공처:

Cardinal Health

INN (국제 이름):

CAPTOPRIL

구성:

CAPTOPRIL 12.5 mg

처방전 유형:

PRESCRIPTION DRUG

승인 상태:

Abbreviated New Drug Application

제품 특성 요약

CAPTOPRIL- CAPTOPRIL TABLET
CARDINAL HEALTH
----------
WARNING: FETAL TOXICITY
•
•
DESCRIPTION
Captopril is a specific competitive inhibitor of angiotensin
I-converting enzyme (ACE), the enzyme
responsible for the conversion of angiotensin I to angiotensin II.
Captopril is designated chemically as
1-[(2S)-3-mercapto-2-methylpropionyl]-L-proline (MW 217.29).
Captopril, USP is a white to off-white crystalline powder that may
have a slight sulfurous odor; it is
soluble in water (approx. 160 mg/mL), methanol, and ethanol and
sparingly soluble in chloroform and
ethyl acetate.
The structural formula is:
C9H15NO3S
Each tablet for oral administration contains 12.5 mg, 25 mg, 50 mg or
100 mg of captopril and the
following inactive ingredients: anhydrous lactose, colloidal silicon
dioxide, crospovidone,
microcrystalline cellulose and stearic acid.
CLINICAL PHARMACOLOGY
MECHANISM OF ACTION
The mechanism of action of captopril has not yet been fully
elucidated. Its beneficial effects in
hypertension and heart failure appear to result primarily from
suppression of the renin-angiotensin-
aldosterone system. However, there is no consistent correlation
between renin levels and response to
the drug. Renin, an enzyme synthesized by the kidneys, is released
into the circulation where it acts on a
plasma globulin substrate to produce angiotensin I, a relatively
inactive decapeptide. Angiotensin I is
then converted by angiotensin converting enzyme (ACE) to angiotensin
II, a potent endogenous
vasoconstrictor substance. Angiotensin II also stimulates aldosterone
secretion from the adrenal cortex,
WHEN PREGNANCY IS DETECTED, DISCONTINUE CAPTOPRIL AS SOON AS POSSIBLE.
DRUGS THAT ACT DIRECTLY ON THE RENIN-ANGIOTENSIN SYSTEM CAN CAUSE
INJURY AND DEATH TO
THE DEVELOPING FETUS. SEE WARNINGS: FETAL TOXICITY.
thereby contributing to sodium and fluid retention.
Captopril prevents the conversion of angiotensin I to angiotensin II
by inhibition of ACE, a
peptidyldipeptide carboxy hydrolase. This inhibition has been
demonstrated in both health